Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...

With the aging of the global population and the rising incidence of neuropsychiatric conditions, the demand for therapeutic drugs is increasing. Consequently, innovations relevant to these medications ...

Beijing, June 11, 2026 - On this day, Bayer and Peking University (PKU) signed the fifth strategic collaboration agreement.

An ad hoc committee will plan and host a 1.5-day public workshop to facilitate discussion focused on the translation of federal investments in biomedical science to innovation in drug development and ...

Pharma R&D is at a crossroads: the pressure to accelerate innovation, ensure compliance and manage fragmented data has never ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Pediatric drug development faces significant challenges, including underfunding, ethical concerns, and complex regulatory frameworks. Despite significant advances in adult drug development, children ...

Triple click chemistry has revolutionized chemical synthesis with its simplicity and efficiency, allowing for the quick and selective assembly of complex molecules. Now, in a recent study, researchers ...

The number of therapies developed in China has doubled in recent years, and approximately one-third of the global licensing ...

Commercialization is a crucial phase in the innovation process and its associated costs significantly influence R&D decisions. Yet our understanding of how commercialization costs impact various ...

Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal changes in the macular, resulting in reduced vision and distorted objects.